IB 

Union Calendar No. 615 

114TH CONGRESS 

2D SESSION H. R. 3537 

[Report No. 114–787, Part I] 

To amend the Controlled Substances Act to clarify how controlled substance 

analogues are to be regulated, and for other purposes. 

IN THE HOUSE OF REPRESENTATIVES 

SEPTEMBER 17, 2015 

Mr. DENT (for himself, Mr. HIMES, Mr. MEEHAN, Mr. DOLD, Mr. TIBERI, 

Mr. COSTELLO of Pennsylvania, Mr. HANNA, Mr. THOMPSON of Pennsylvania, Mr. ROGERS of Kentucky, Mr. MURPHY of Pennsylvania, Mr. 

BARLETTA, Ms. NORTON, Mr. LANCE, Mrs. COMSTOCK, Mr. KATKO, Ms. 

ROS-LEHTINEN, and Mr. JOLLY) introduced the following bill; which was 

referred to the Committee on Energy and Commerce, and in addition to 

the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions 

as fall within the jurisdiction of the committee concerned 

SEPTEMBER 26, 2016 

Additional sponsors: Mr. RODNEY DAVIS of Illinois, Mr. CUELLAR, Mr. GUTHRIE, Mr. THORNBERRY, Mr. BISHOP of Michigan, Mr. KING of New 

York, Mr. ALLEN, Mr. PIERLUISI, Ms. KAPTUR, Mr. PETERS, and Ms. 

VELA ́ZQUEZ

SEPTEMBER 26, 2016 

Reported from the Committee on Energy and Commerce with amendments 

[Strike out all after the enacting clause and insert the part printed in italic] 

SEPTEMBER 26, 2016 

The Committee on the Judiciary discharged; committed to the Committee of 

the Whole House on the State of the Union and ordered to be printed 

[For text of introduced bill, see copy of bill as introduced on September 17, 2015] 


srobinson on DSK5SPTVN1PROD with BILLS
2 

•HR 3537 RH

A BILL 

To amend the Controlled Substances Act to clarify how controlled substance analogues are to be regulated, and for 

other purposes. 


srobinson on DSK5SPTVN1PROD with BILLS
3 

•HR 3537 RH

1 Be it enacted by the Senate and House of Representa2 tives of the United States of America in Congress assembled, 

3 SECTION 1. SHORT TITLE. 

4 This Act may be cited as the ‘‘Dangerous Synthetic 

5 Drug Control Act of 2016’’. 

6 SEC. 2. TREATMENT OF CERTAIN DESIGNER DRUGS AS 

7 SCHEDULE I CONTROLLED SUBSTANCES. 

8 (a) CANNABIMIMETIC AGENTS.—Schedule I, as set 

9 forth in section 202(c) of the Controlled Substances Act (21 

10 U.S.C. 812(c)), is amended in subsection (d)(2)(B)— 

11 (1) in clause (xiv) by striking ‘‘and’’ at the end; 

12 (2) in clause (xv) by striking the period and in13 serting a semicolon; and 

14 (3) by adding at the end the following: 

15 ‘‘(xvi) 2-(2-methylphenyl)-1-(1-pentyl-1H16 indol-3-yl)ethanone (JWH–251); 

17 ‘‘(xvii) (1-butyl-1H-indol-3-yl)(4- 

18 methylnaphthalen-1-yl)methanone (4′-methyl 

19 JWH–073); 

20 ‘‘(xviii) 2-(3-methoxyphenyl)-1-(1-pentyl21 1H-indol-3-yl)ethanone (JWH–302); 

22 ‘‘(xix) N-(adamantan-1-yl)-1-(5- 

23 fluoropentyl)-1H-indole-3-carboxamide (5F– 

24 APICA); 


srobinson on DSK5SPTVN1PROD with BILLS
4 

•HR 3537 RH

1 ‘‘(xx) quinolin-8-yl 1-(5-fluoropentyl)-1H2 indole-3-carboxylate (5F–PB–22); 

3 ‘‘(xxi) N-(1-amino-3-methyl-1-oxobutan-2- 

4 yl)-1-pentyl-1H-indazole-3-carboxamide (AB– 

5 PINACA); 

6 ‘‘(xxii) N-(naphthalen-1-yl)-1-pentyl-1H7 indole-3-carboxamide (MN–24); 

8 ‘‘(xxiii) (1-(5-fluoropentyl)-1H-indazol-3- 

9 yl)(naphthalen-1-yl)methanone (THJ–2201); 

10 ‘‘(xxiv) N-(1-amino-3,3-dimethyl-1- 

11 oxobutan-2-yl)-1-pentyl-1H-indazole-3- 

12 carboxamide (ADBICA); 

13 ‘‘(xxv) methyl 2-(1-(5-fluoropentyl)-1H-in14 dazole-3-carboxamido)-3-methylbutanoate (5F– 

15 AMB); and 

16 ‘‘(xxvi) methyl 2-(1-(cyclohexylmethyl)-1H17 indazole-3-carboxamido)-3-methylbutanoate 

18 (MA–CHMINACA).’’. 

19 (b) SYNTHETIC OPIOIDS.—Schedule I, as set forth in 

20 section 202(c) of the Controlled Substances Act (21 U.S.C. 

21 812(c)), is amended in subsection (a) by adding at the end 

22 the following: 

23 ‘‘(43) Butyryl fentanyl. 

24 ‘‘(44) beta-Hydroxythiofentanyl. 

25 ‘‘(45) Acetyl fentanyl.’’. 


srobinson on DSK5SPTVN1PROD with BILLS
5 

•HR 3537 RH

1 (c) OTHER DRUGS.—Schedule I, as set forth in section 

2 202(c) of the Controlled Substances Act (21 U.S.C. 812(c)), 

3 is amended in subsection (c) by adding at the end the fol4 lowing: 

5 ‘‘(29) 1-(naphthalen-1-yl)-2-(pyrrolidin-1- 

6 yl)pentan-1-one (α-naphyrone). 

7 ‘‘(30) 1-(2,3-dihydrobenzofuran-5-yl)propan-2- 

8 amine (5–APDB). 

9 ‘‘(31) 1-(2,3-dihydrobenzofuran-6-yl)propan-2- 

10 amine (6–APDB). 

11 ‘‘(32) 6,7-dihydro-5H-indeno[5,6-d][1,3]dioxol-6- 

12 amine (MDAI). 

13 ‘‘(33) 5-iodo-2,3-dihydro-1H-inden-2-amine (5– 

14 IAI). 

15 ‘‘(34) 1-(4-bromofuro[2,3-f]benzofuran-8- 

16 yl)propan-2-amine (bromo-dragonfly). 

17 ‘‘(35) 1-(4-chloro-2,5-dimethoxyphenyl)propan-2- 

18 amine (DOC). 

19 ‘‘(36) 1-(4-ethoxy-2,5-dimethoxyphenyl)propan-2- 

20 amine (MEM).’’. 

Amend the title so as to read: ‘‘A bill to amend the 

Controlled Substances Act to add certain synthetic substances to schedule I, and for other purposes.’’. 


srobinson on DSK5SPTVN1PROD with BILLS
Union Calendar No. 615 

114TH CONGRESS 

2D SESSION H. R. 3537 

[Report No. 114–787, Part I] 

A BILL 

To amend the Controlled Substances Act to clarify 

ulated, and for other purposes. how controlled substance analogues are to be regSEPTEMBER 26, 2016 

Reported from the Committee on Energy and Commerce 

with amendments 

SEPTEMBER 26, 2016 

The Committee on the Judiciary discharged; committed 

the Union and ordered to be printed to the Committee of the Whole House on the State of 


srobinson on DSK5SPTVN1PROD with BILLS